tradingkey.logo
tradingkey.logo
Search

Bio Rad Laboratories Inc

BIO
Add to Watchlist
243.510USD
+1.800+0.74%
Close 05/13, 16:00ETQuotes delayed by 15 min
6.57BMarket Cap
40.38P/E TTM

Bio Rad Laboratories Inc

243.510
+1.800+0.74%

More Details of Bio Rad Laboratories Inc Company

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Bio Rad Laboratories Inc Info

Ticker SymbolBIO
Company nameBio Rad Laboratories Inc
IPO dateMar 17, 1980
CEOSchwartz (Norman D)
Number of employees7700
Security typeOrdinary Share
Fiscal year-endMar 17
Address1000 Alfred Nobel Dr
CityHERCULES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code94547
Phone15107247000
Websitehttps://www.bio-rad.com/
Ticker SymbolBIO
IPO dateMar 17, 1980
CEOSchwartz (Norman D)

Company Executives of Bio Rad Laboratories Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
-1.00%
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
19.55K
+5.48%
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
2.02K
+35.01%
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
1.22K
+33.50%
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
896.00
+82.48%
Ms. Courtney C Enloe
Ms. Courtney C Enloe
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
721.00
+15.12%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
715.00
+56.92%
Mr. Arnold A. Pinkston
Mr. Arnold A. Pinkston
Independent Director
Independent Director
715.00
+56.92%
Ms. Melinda Litherland
Ms. Melinda Litherland
Independent Director
Independent Director
308.00
--
Rajat Mehta
Rajat Mehta
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
58.00
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
-1.00%
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
19.55K
+5.48%
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
2.02K
+35.01%
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
1.22K
+33.50%
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
896.00
+82.48%
Ms. Courtney C Enloe
Ms. Courtney C Enloe
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
721.00
+15.12%

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.02B
39.59%
Europe
881.80M
34.14%
APAC
513.30M
19.87%
Other
165.40M
6.40%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
First Eagle Investment Management, L.L.C.
11.85%
Alice N. Schwartz Revocable Trust
8.21%
BlackRock Institutional Trust Company, N.A.
6.73%
Schwartz (Norman D)
6.36%
Dimensional Fund Advisors, L.P.
5.02%
Other
61.84%
Shareholders
Shareholders
Proportion
First Eagle Investment Management, L.L.C.
11.85%
Alice N. Schwartz Revocable Trust
8.21%
BlackRock Institutional Trust Company, N.A.
6.73%
Schwartz (Norman D)
6.36%
Dimensional Fund Advisors, L.P.
5.02%
Other
61.84%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
44.15%
Investment Advisor
40.11%
Individual Investor
8.27%
Corporation
8.21%
Hedge Fund
4.12%
Research Firm
2.06%
Pension Fund
1.08%
Bank and Trust
0.89%
Sovereign Wealth Fund
0.53%

Institutional Shareholding

Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1041
18.42M
84.86%
-4.19M
2025Q4
1040
20.58M
101.60%
-3.97K
2025Q3
1095
20.58M
103.17%
+603.60K
2025Q2
1114
19.81M
108.02%
-855.27K
2025Q1
1146
19.96M
99.31%
-2.83M
2024Q4
1140
19.39M
101.48%
-657.49K
2024Q3
1121
20.03M
101.42%
-386.71K
2024Q2
1139
20.32M
91.46%
+1.29M
2024Q1
1154
19.07M
91.02%
-2.25M
2023Q4
1187
19.09M
89.28%
-259.69K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
First Eagle Investment Management, L.L.C.
2.57M
11.72%
+50.15K
+1.99%
Dec 31, 2025
Alice N. Schwartz Revocable Trust
1.78M
8.13%
--
--
Feb 23, 2026
BlackRock Institutional Trust Company, N.A.
1.46M
6.66%
-23.75K
-1.60%
Dec 31, 2025
Schwartz (Norman D)
1.38M
6.3%
-13.77K
-0.99%
Feb 23, 2026
Dimensional Fund Advisors, L.P.
1.08M
4.91%
+14.13K
+1.33%
Dec 31, 2025
Ariel Investments, LLC
764.67K
3.49%
-44.81K
-5.54%
Dec 31, 2025
EARNEST Partners, LLC
603.59K
2.75%
-5.69K
-0.93%
Dec 31, 2025
State Street Investment Management (US)
559.60K
2.55%
-11.99K
-2.10%
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Parnassus Value Select ETF
3.94%
First Trust Indxx Medical Devices ETF
2.15%
ROBO Global Healthcare Technology & Innovation ETF
1.61%
Schwab Ariel Opportunities ETF
1.6%
First Trust Health Care Alphadex Fund
1.49%
FPA Global Equity ETF
1.38%
First Eagle Global Equity ETF
1.21%
iShares Health Innovation Active ETF
1.17%
Pacer US Export Leaders ETF
1.03%
Harbor Health Care ETF
0.82%
View more
Parnassus Value Select ETF
Proportion3.94%
First Trust Indxx Medical Devices ETF
Proportion2.15%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.61%
Schwab Ariel Opportunities ETF
Proportion1.6%
First Trust Health Care Alphadex Fund
Proportion1.49%
FPA Global Equity ETF
Proportion1.38%
First Eagle Global Equity ETF
Proportion1.21%
iShares Health Innovation Active ETF
Proportion1.17%
Pacer US Export Leaders ETF
Proportion1.03%
Harbor Health Care ETF
Proportion0.82%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI